CRS members receive a free online subscription
Drug Delivery and Translational Research is a journal published by CRS, providing a unique forum for scientific publication of high-quality research that is exclusively focused on translational aspects of drug delivery. The journal is published 6 times a year and will be available online to CRS members as part of their annual dues.
We welcome research focused on the following areas of translational drug delivery research:
- Designing and developing novel drug delivery systems, with a focus on their application to disease conditions
- Preclinical and clinical data related to drug delivery systems
- Drug distribution, pharmacokinetics, clearance, with drug delivery systems as compared to traditional dosing to demonstrate beneficial outcomes
- Short-term and long-term biocompatibility of drug delivery systems, host response
- Biomaterials with growth factors for stem-cell differentiation in regenerative medicine and tissue engineering
- Image-guided drug therapy
- Devices for drug delivery and drug/device combination products
In addition to original full-length papers, communications, and reviews, the journal will also include editorials, reports of future meetings, research highlights, and announcements pertaining to the activities of CRS.
“A timely and truly insightful Inspirational Note by one of the fathers of nanotechnology & pharmaceuticals.” -Jung Soo Suk, Ph.D., Assistant Professor, The Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine
"In this 'Inspirational Note' you will be inspired by the way industry sees advances in drug delivery and Nanomedicine. Dr. Marianne Ashford talks about the 'increasing momentum'. You should not miss this note if you are interested in translational research." -Prof. Maria José Alonso, Editor-in-Chief of the Drug Delivery and Translational Research (DDTR) Journal, Past President of the Controlled Release Society
Best Paper of the February 2021 Issue of DDTR: Injection route affects intra-articular hyaluronic acid distribution and clinical outcome in viscosupplementation treatment for knee osteoarthritis: a combined cadaver study and randomized clinical trial
Summary: Intra-articular hyaluronic acid (HA) injection is an effective and safe treatment for patients with mild-to-moderate knee osteoarthritis, which relieves pain and improves joint function. Injection through medial midpatellar (MMP) route is observed to provide a greater coverage of HA throughout the vulnerable regions of the articular cartilage in osteoarthritic knee compare to anteromedial (AM) route. Specifically, intra-articular HA with MMP injection route showed a nearly full coverage of patellofemoral joint and a large coverage of medial femorotibial joint, as well as a half coverage of lateral femorotibial joint. Correspondingly, injection through the MMP route is superior to AM route in achieving pain relief and global patient satisfaction. To this end, intra-articular HA injection through the MMP route is recommended for patients with mild-to-moderate knee osteoarthritis in the future clinical practice.
2019 DDTR Best Paper of the Year: Depletion of collagen by losartan to improve tumor accumulation and therapeutic efficacy of photodynamic nanoplatforms
2019 CRS Nanomedicine and Nanoscale Delivery (NND) Best Paper of the Year: Tumor growth inhibition by mSTEAP peptide nanovaccine inducing augmented CD8+ T cell immune responses
2019 DDTR CRS Oral Drug Delivery Focus Group Paper of the Year Award: Loratadine self-microemulsifying drug delivery systems (SMEDDS) in combination with sulforaphane for the synergistic chemoprevention of pancreatic cancer
Read DDTR's First Inspirational Note: Contraceptive technologies for global health: ethically getting to safe, effective and acceptable options for women and men
Maria José Alonso, PhD - University of Santiago de Complotela, Spain